Cardiol Therapeutics INC. (CRDL) — 6-K Filings

All 6-K filings from Cardiol Therapeutics INC.. Browse 50 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (50)

Cardiol Therapeutics Files 6-K Report — Apr 14, 2026 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on April 14, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K for
Cardiol Therapeutics Files 6-K Report — Apr 10, 2026 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on April 10, 2026, reporting information as a foreign issuer. The filing includes documents such as the 6-K form itse
Cardiol Therapeutics Files 6-K Report — Apr 1, 2026 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on April 1, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K form
6-K Filing — Dec 1, 2025
6-K Filing — Nov 13, 2025
Cardiol Therapeutics Secures U.S. Patent for Heart Drugs Until 2040 — Nov 13, 2025 Risk: low
Cardiol Therapeutics Inc. announced on November 13, 2025, that it has received a U.S. patent allowance for its heart drugs, providing broad protection until lat
6-K Filing — Nov 5, 2025
Cardiol Therapeutics Files 6-K with Exempt Distribution Report — Oct 28, 2025 Risk: medium
Cardiol Therapeutics Inc. filed a Form 6-K on October 28, 2025, reporting on activities for the month of October 2025. The filing includes Exhibit 99.1, a Form
Cardiol Therapeutics Files Material Change Report — Oct 27, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on October 27, 2025, reporting a Material Change Report dated October 27, 2025. The company, based in Oakville, Ontar
Cardiol Therapeutics Raises $11.4M, Extends Cash Runway — Oct 21, 2025 Risk: medium
Cardiol Therapeutics Inc. announced on October 21, 2025, that it has successfully completed a financing round, raising US$11.4 million. This funding is expected
Cardiol Therapeutics Secures $11M Financing — Oct 17, 2025 Risk: medium
Cardiol Therapeutics Inc. announced on October 17, 2025, that it has secured US$11 million in financing. This funding is expected to extend the company's cash r
Cardiol Therapeutics Files Q2 2025 Results — Aug 14, 2025 Risk: medium
Cardiol Therapeutics Inc. filed a Form 6-K on August 14, 2025, reporting its financial results for the three and six months ended June 30, 2025. The filing incl
Cardiol Therapeutics to Speak at Canaccord Growth Conference — Aug 11, 2025 Risk: low
Cardiol Therapeutics Inc. announced on August 11, 2025, its participation in a fireside chat at Canaccord Genuity's 45th Annual Growth Conference. The company,
Cardiol Therapeutics Announces Phase II Trial Results — Aug 6, 2025 Risk: medium
Cardiol Therapeutics Inc. announced topline results from its Phase II ARCHER trial of CardiolRx™ in acute myocarditis on August 6, 2025. The company filed a For
Cardiol Therapeutics Locks Phase II ARCHER Trial Database — Jul 22, 2025 Risk: medium
Cardiol Therapeutics Inc. announced on July 22, 2025, that it has achieved database lock for its Phase II ARCHER trial of CardiolRx™ in patients with acute myoc
Cardiol Therapeutics Reports 2025 AGM Results — May 29, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on May 29, 2025, reporting the results of its 2025 Annual General Meeting of Shareholders. The filing includes a news
Cardiol Therapeutics to Webcast Annual Shareholder Meeting — May 27, 2025 Risk: low
Cardiol Therapeutics Inc. announced on May 27, 2025, that it will webcast its Virtual Annual General Meeting of Shareholders on May 28, 2025, at 4:30 p.m. EDT.
Cardiol Therapeutics Files May 2025 6-K with Q1 Financials — May 14, 2025 Risk: medium
Cardiol Therapeutics Inc. filed a Form 6-K on May 14, 2025, reporting on its activities for the month of May 2025. The filing includes condensed interim consoli
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board — Apr 29, 2025 Risk: low
Cardiol Therapeutics Inc. announced on April 29, 2025, the nomination of Dr. Timothy Garnett to its Board of Directors. Dr. Garnett brings extensive experience
Cardiol Therapeutics Files 6-K for April 2025 Shareholder Meeting — Apr 28, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on April 28, 2025, for the month of April 2025. The filing includes several exhibits related to their Annual General
Cardiol Therapeutics Files 6-K — Apr 16, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on April 16, 2025, to report a news release dated April 16, 2025. The filing does not contain specific financial figu
Cardiol Therapeutics Files 6-K with April News Release — Apr 1, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on April 1, 2025, reporting for the month of April 2025. The filing includes a news release dated April 1, 2025, as E
Cardiol Therapeutics Files 6-K with Meeting Notice — Mar 14, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on March 14, 2025, reporting a Notice of Meeting and Record Date dated March 14, 2025. The company, headquartered in
Cardiol Therapeutics Files 6-K Report — Mar 3, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on March 3, 2025, reporting information for the month of March 2025. The filing includes a news release dated March 3
Cardiol Therapeutics Files 6-K for February 2025 — Feb 20, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on February 20, 2025, reporting for the month of February 2025. The filing, submitted by newsfilecorp.com, includes E
Cardiol Therapeutics Files 6-K for February 2025 — Feb 4, 2025 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on February 4, 2025, reporting for the month of February 2025. The filing indicates that the company is a foreign pri
Cardiol Therapeutics Files 6-K Report — Nov 18, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on November 18, 2024, reporting for the month of November 2024. The filing includes Exhibit 99.1, which is a news rel
Cardiol Therapeutics Files 6-K with Q3 Financials — Nov 14, 2024 Risk: medium
Cardiol Therapeutics Inc. filed a 6-K report on November 14, 2024, for the period ending September 30, 2024. The filing includes condensed interim consolidated
Cardiol Therapeutics Files 6-K, Reports for October 2024 — Oct 22, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on October 22, 2024, reporting for the month of October 2024. The company, based in Oakville, Ontario, Canada, is inv
Cardiol Therapeutics Closes $10M Financing — Oct 11, 2024 Risk: medium
On October 11, 2024, Cardiol Therapeutics Inc. announced the closing of its previously announced bought-deal financing, which included the exercise of the over-
Cardiol Therapeutics Closes $13.5M Public Offering — Oct 10, 2024 Risk: medium
Cardiol Therapeutics Inc. announced the closing of a public offering on October 10, 2024, raising US$13.5 million. The company, headquartered in Oakville, Ontar
Cardiol Therapeutics Inc. Files 6-K, Incorporates Exhibit — Oct 9, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on October 9, 2024, to incorporate Exhibit 99.1 by reference into its existing Registration Statement on Form F-10 (F
Cardiol Therapeutics Files 6-K, Incorporates Exhibits — Oct 8, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on October 8, 2024, incorporating Exhibits 99.1 and 99.2 by reference into its Form F-10 registration statement (File
Cardiol Therapeutics Files 6-K, Includes News Release — Sep 24, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on September 24, 2024, reporting for the month of September 2024. The filing indicates that the company is a foreign
Cardiol Therapeutics Files 6-K Report — Sep 10, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on September 10, 2024, to report information for the month of September 2024. The filing includes Exhibit 99.1, which
Cardiol Therapeutics Files 6-K with Financials — Aug 12, 2024 Risk: low
Cardiol Therapeutics Inc. filed a 6-K report on August 12, 2024, for the period ending June 30, 2024. The filing includes condensed interim consolidated financi
Cardiol Therapeutics Inc. Files 6-K, Incorporates Exhibit — Jul 16, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on July 16, 2024, incorporating Exhibit 99.1 into its existing Registration Statement on Form F-10 (File No. 333-2807
Cardiol Therapeutics Files 6-K with News Release — Jun 27, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on June 27, 2024, reporting a news release as an exhibit. The company, based in Oakville, Ontario, Canada, operates i
Cardiol Therapeutics Files 6-K Report — Jun 25, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on June 25, 2024, reporting a news release dated June 2024. The company, based in Oakville, Ontario, Canada, is invol
Cardiol Therapeutics Files 6-K with News Release — Jun 13, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on June 13, 2024, reporting information for the month of June 2024. The filing includes a news release dated June 13,
Cardiol Therapeutics Files Annual Meeting Documents — May 28, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on May 28, 2024, to report on its Annual General Meeting of Shareholders. The filing includes the Notice of Annual Ge
Cardiol Therapeutics Files Q1 2024 Financial Update — May 14, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on May 14, 2024, reporting its condensed interim consolidated financial statements and management's discussion and an
Cardiol Therapeutics Files 6-K — May 14, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on May 14, 2024, reporting a news release dated May 14, 2024. The company is incorporated in Canada and its principal
Cardiol Therapeutics Files 6-K with Meeting Notice — Apr 26, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on April 26, 2024, reporting for the month of April 2024. The filing includes Exhibit 99.1, which is a Notice of Meet
Cardiol Therapeutics Files 6-K Report — Apr 2, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K on April 2, 2024, to report information for the month of April 2024. The filing includes Exhibit 99.1, which is a new
Cardiol Therapeutics Files 6-K, Confirms 20-F Reporting — Feb 26, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K with the SEC on February 26, 2024, indicating it is a foreign private issuer. The filing confirms the company submits
Cardiol Therapeutics Files 6-K, Confirms 20-F Annual Reporting — Feb 21, 2024 Risk: low
Cardiol Therapeutics Inc. filed a Form 6-K with the SEC on February 21, 2024, indicating its status as a foreign private issuer. The filing confirms the company
Cardiol Therapeutics Files Routine 6-K for News Release — Feb 15, 2024 Risk: low
Cardiol Therapeutics Inc., a foreign private issuer, filed a Form 6-K with the United States Securities and Exchange Commission on February 15, 2024. The purpos
Cardiol Therapeutics Regains Nasdaq Compliance, Averting Delisting Risk — Jan 24, 2024
Cardiol Therapeutics Inc. announced on January 24, 2024, that it has regained full compliance with all Nasdaq Capital Market listing standards. This is signific
Cardiol Therapeutics Exceeds 50% Enrollment in ARCHER Trial — Jan 9, 2024
Cardiol Therapeutics Inc. announced on January 9, 2024, that it has exceeded 50% enrollment in its Phase II ARCHER trial, which is studying a treatment for acut

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX